Inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis, are known to increase a person’s risk of developing bowel cancer. However, a new genome sequencing test may offer deeper insight into who is most vulnerable.
By analysing specific genetic markers, this testing approach developed by scientists at the Institute of Cancer Research, aims to predict bowel cancer risk more accurately. In turn, this leads to proactive screening and personalised care.
Here, we’ll explore why understanding your risk level matters, how this new DNA testing works, and what it could mean for patients with IBD moving forward.
Understanding your risk
When you live with an inflammatory bowel disease, you quickly become familiar with the challenges it can bring, from managing flare-ups to maintaining a balanced diet that supports intestinal health. Beyond these day-to-day considerations, there’s a longer-term concern for many patients – the increased likelihood of developing bowel cancer over time.
Traditional guidelines typically suggest that people with IBD should undergo regular colonoscopies, but timing and frequency can vary significantly from one patient to another.
By pinpointing genetic markers associated with a higher propensity for cancerous changes, surveillance can be tailored to each patient’s unique needs. In turn, those who are flagged with a higher risk could begin screening earlier and more frequently, potentially catching cancer at its earliest stages when it’s most treatable.
New DNA testing predicts risk of bowel cancer in people with IBD
Recent research, including a study published in Gut, reveals the value of genome sequencing for people living with IBD. By closely examining variations in specific genes, this testing technique can reveal whether certain genetic ‘red flags’ for bowel cancer are present.
These variations could influence how cells respond to chronic inflammation in the intestinal tract, or how effectively they repair DNA damage over time.
The new test takes advantage of modern sequencing technologies, which are now more accessible and accurate than ever. Scientists examine segments of your DNA for mutations or patterns linked with higher cancer risk. The process is typically performed using a small blood sample, and results are then interpreted alongside clinical information like age, history of flare-ups, and length of time a person has had IBD.
This combined data builds a clearer overall risk profile, guiding discussions about enhanced surveillance schedules and potential interventions.
Patients with IBD
Looking ahead, routine genetic testing may well become part of the standard care for people with IBD. This approach could usher in a new era of precision medicine, where each patient’s care plan is carefully tailored to their unique genetic makeup, disease history, and personal preferences.
Early detection remains key to successfully treating bowel cancer, and genome sequencing represents a proactive step toward catching changes before they progress to something more serious.
For those at heightened risk, regular check-ups, colonoscopies, and close monitoring can make a significant difference. If a cancerous lesion is identified, early intervention can vastly improve outcomes.
If you are living with IBD or are experiencing abdominal symptoms and would like to arrange a consultation to discuss surveillance and treatments, call 01926 436367 to book an appointment.
